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Background: Pigmented villonodular synovitis (PVNS) is
considered to be a neoplastic-like disorder of the synovium
histologically characterised by villonodular hyperplasia,
resulting in dense fibrosis and haemosiderin deposition.
The pathogenesis of the disease is still unknown.
Case report: A patient presented with severe treatment
resistant PVNS of the right knee joint. Several conventional
treatment regimens, including open surgical synovectomy
and intra-articular injections of yttrium-90 (90Y) failed to
control the disease. After finding marked tumour necrosis
factor a (TNFa) expression in arthroscopic synovial tissue
samples, treatment with an anti-TNFa monoclonal antibody
(infliximab) at a dose of 5 mg/kg was started. Additional
courses with the same dose given 2, 6, 14, and 20 weeks
later, and bimonthly thereafter up to 54 weeks, controlled the
signs and symptoms. Immunohistological analysis at follow
up identified a marked reduction in macrophage numbers
and TNFa expression in the synovium.
Discussion: This is probably the first case which describes
treatment with TNFa blockade of PVNS in a patient who is
refractory to conventional treatment. It provides the rationale
for larger controlled studies to elucidate further the efficacy of
TNFa blockade treatment in refractory PVNS.
I
n 1941 Jaffe et al described pigmented villonodular
synovitis (PVNS) as an inflammatory and reactive disease
of synovial tissues caused by uncertain trauma of the joint.1
Since then, localised and diffuse forms of synovial disease
have been reported.2–5 In general, the disease is considered to
be a premalignant disease because of its effects on joint
structures and integrity, although its exact cause remains
unknown.2–5 The most commonly affected site is the knee,
but it can be present in any synovial joint. PVNS is a rare
disease with an annual incidence of 1.8 and a prevalence of
9.2 patients per million population.2 6 Untreated it can result
in severe joint damage with accompanying disability.
Therefore, PVNS is treated aggressively; the preferred
treatment is surgical synovectomy (either arthroscopically
or open), eventually followed by radiosynovectomy with
intra-articular injection of yttrium-90 (90Y).3 Nevertheless,
the disease may reoccur after these treatments. A recurrence
rate of between 25 and 45% has been reported.3
Recently, the presence of macrophages and related proin-
flammatory cytokines such as tumour necrosis factor (TNF)a
has been described in PVNS.7 8 These findings offer new
insights into the pathomechanism of PVNS by suggesting
that periarticular bone resorption and cartilage destruction
which characterise PVNS may be related to the expression of
proinflammatory cytokines, which in turn stimulate matrix
metalloproteinase production. As a consequence, TNFa
blockade might be a new therapeutic option for stopping,
or at least delaying, destruction in refractory PVNS.
Currently, no cases of TNFa targeted treatment have been
reported.
CASE REPORT
In 1994 a 22 year old man, presented with monarthritis of
the right knee joint. A diagnosis of the localised form of
PVNS was made by arthroscopy and confirmed by histolo-
gical examination. In 1995 an open surgical synovectomy was
performed because of persistent disease. The result of this
treatment was unsatisfactory and the disease recurred in
1996. Magnetic resonance imaging (MRI) showed enhanced
synovium surrounding the haemosiderin deposits, indicating
persistent synovitis located posterior in the knee joint and an
intercondylar erosion with a diameter of 1 cm. Treatment
with an intra-articular injection of 90Y was performed. The
results of this procedure were unsatisfactory, and the patient
was re-treated 6 months later with an intra-articular injec-
tion of 90Y in 1997. After this second intra-articular injection
the disease recurred and was controlled by aspiration of
synovial fluid and steroids administered locally .
During the following years the disease affected activities of
daily life (ADL) in such a way that patient had to stop
working as a mechanic and changed to an administrative job.
During these years radiological examination including plain
radiography, computed tomography, and MRI scanning was
performed periodically. MRI scanning performed in 1998
showed progression of the disease posterior in the knee joint,
progression of effusion, and the existence of the already
described intercondylar erosion with a diameter of still 1 cm.
On MRI scanning at the end of 2002, just before treatment
with anti-TNFa was started, progressive damage was seen,
characterised by hyperproliferative synovium in the complete
knee joint, destruction of the cartilage, increase of the
intercondylar erosion up to a diameter of 2 cm, and
occurrence of several other small erosions.
Because of this progressive radiological damage, persisting
synovitis with effusion (70–80 ml), and progressive limita-
tions in ADL, additional analysis of the local pathology was
justified. Therefore an arthroscopy of the knee was performed
to provide more insight into the pathogenesis of the disease
and to evaluate possible treatment options (fig 1A).
Subsequently multiple synovial samples were obtained as
described previously.9 At routine histopathology classical
histological features were seen, with pigment depositions
and an impressive infiltrate. Immunohistology showed that
this infiltrate mainly consisted of CD68+ macrophages (clone
EBM11; DAKO, Glostrup, Denmark) with abundant presence
of anti-TNFa (IP-300;Genzyme) (fig 2).
In response to these findings and the lack of efficacy of
conventional treatment, infliximab (5 mg/kg body weight)
Abbreviations: ADL, activities of daily living; MRI, magnetic resonance
imaging; PVNS, pigmented villonodular synovitis; RA, rheumatoid
arthritis; TNFa, tumour necrosis factor a
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and methotrexate (10 mg/week) was started, which was well
tolerated by the patient. Additional courses were adminis-
tered 2, 6, 14, and 20 weeks later at the same dose; later
courses were given at 8 week intervals up to 54 weeks.
During the initial 20 weeks of treatment with anti-TNFa
the knee was punctured every 4 weeks for persisting effusion,
without instillation of intra-articular corticosteroids. The
initial volume was 80 ml and this gradually reduced to
30 ml. After the fourth infusion with infliximab at 20 weeks,
no synovial fluid could be obtained and the ADL improved
considerably. For example, the patient could stand on several
consecutive days again without experiencing any pain in the
knee joint, which was impossible for him before treatment
with infliximab.
To evaluate the histological changes at 20 weeks, a second
set of synovial biopsy specimens was obtained by arthroscopy
(figs 1B and 2). A dramatic reduction in cellularity (baseline
1.76109 cells/l, 20 weeks 0.76109 cells/l), number of macro-
phages (baseline 1.66109 cells/l; 20 weeks 0.66109 cells/l),
estimated pigment (baseline integrated optical density (IOD)
0.66109/l; 20 weeks 2.1/l), and TNFa (baseline IOD
236.16109/l, 20 weeks 125.56109/l) was seen.
Based on the response to treatment with infliximab, it was
decided to continue treatment with infliximab bimonthly to
control local disease activity. MRI scanning performed
10 months after treatment with infliximab showed neither
progression nor regression of the synovial tumour mass but
also no new or larger erosions in comparison with MRI
scanning just before treatment. In conclusion, the patient
responded well to this therapeutic regimen with infliximab
up to 54 weeks of treatment, without any side effects.
DISCUSSION
This case is, to our knowledge, the first to demonstrate the
efficacy of infliximab treatment in refractory PVNS. After 20
weeks of infliximab treatment marked clinical improvement
was seen, and the number of synovial tissue macrophages
was considerably reduced.
TNFa blockade was considered as a therapeutic option in
our patient with refractory PVNS for several reasons. Firstly,
macrophages and related proinflammatory cytokines such as
TNFa have been reported to be important in PVNS.7 8 In our
case this could be confirmed. Secondly, it has been
demonstrated that in patients with rheumatoid arthritis
Figure 1 Macroscopic examination of the synovium before (A) and after (B) 20 weeks of treatment with anti-TNFa. (A) Hypertrophied synovium
with villous transformation and haemosiderin deposition. (B) Reduction of hypertrophied synovium and haemosiderin deposition.
Figure 2 Pathological specimen of pigmented villonodular synovitis before and after 20 weeks of treatment with anti-TNFa. Before treatment: classic
histological features were seen, with pigment depositions and an impressive infiltrate, mainly consisting of macrophages with an abundant presence of
TNFa, and immunohistochemical staining for macrophages and TNFa at baseline. After treatment: a dramatic reduction in cellularity, number of
macrophages, estimated pigment, and TNFa after 20 weeks of treatment with anti-TNFa was seen.
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(RA), infliximab reduces the number of inflammatory cells in
synovial tissue as soon as 48 hours after the start of
treatment.10 In RA it has been demonstrated that there is a
close relation between the magnitude of local inflammation
and macrophages and their related cytokines.11 12 Therefore,
targeting macrophages and related cytokines could be
important in other diseases such as PVNS where macro-
phages are predominant cells.
TNFa is believed to have a key role in the pathogenesis of
RA.10 Because large amounts of TNFa were found in PVNS,
we suggested that TNFa might also have a similar role in the
pathogenesis of PVNS. Up to now PVNS has been considered
to be a neoplastic-like disorder of the synovium, with
synovitis as a secondary reaction in PVNS.2 4 Yudoh et al
suggested that the pathological mechanism for growth of
hypertrophic villi in PVNS is different from synovial growth
in RA.4 Synovial hyperplasia in PVNS might be due to up
regulation of synoviocyte proliferation as represented by
activation of telomerase, which is evident in the majority of
tumour cell lines.4 From this point of view it is not surprising
that treatment with TNFa blockade did not reduce the
synovial tumour mass as measured by MRI. However a
marked decrease in macrophages and TNFa production
might have stopped, or at least delayed, the destructive
potency of this tumour in our patient.
In RA, TNFa blockade results in immediate clinical
improvement and reduced macrophage infiltration in the
synovium.10 In our patient disease control was only achieved
after a few months, with persisting effusion of the knee
during the first months of treatment, even with the markedly
higher dose of infliximab (5 mg/kg) in comparison with the
dose used in a previous synovial biopsy study in patients with
RA (3 mg/kg). This slower disease control might have been
caused by the greater hyperplasia of the synovium observed
in our patient.
To our knowledge, this is the first case of TNFa targeted
treatment resulting in clinical and histological disease control
in refractory PVNS. Debulking surgery, eventually followed
by intra-articular 90Y or radiation treatment, remains the first
step for treatment of PVNS. Our report suggests that larger
clinical studies with long term follow up are needed in order
to determine the effects of infliximab on structural damage
and possibly to delay significant surgery such as joint
replacement in patients with PVNS with relapsing disease
after open surgery and treatment with 90Y.
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